Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in Japanese prostate cancer patients with slightly elevated serum PSA levels

Japanese Journal of Clinical Oncology

Volumn 29, Issue 12, 1999, Pages 617-622

  Kuriyama, Manabu ^a   Uno, Hiromi ^a   Watanabe, Hiroki ^b   Yamanaka, Hidetoshi ^c   Saito, Yutaka ^d   Shida, Keizo ^e  

^a GIFU UNIVERSITY   (Japan)

^b MEIJI UNIVERSITY OF INTEGRATIVE MEDICINE   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d Sasebo Shiritsu Sogo Hospital   (Japan)

^e Foundation for the Promotion of Cancer Research (Japan)   (Japan)

Author keywords

F T; Prostate cancer; Prostatic volume; PSA gray zone; PSAD

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; AGED; ARTICLE; BIOPSY; BLOOD; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE; PROSTATE TUMOR; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 0033254124     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/29.12.617     Document Type: Article

References (23)

1. Kuriyama M. Prostate-specific antigen as a tumor marker in prostate cancer. Int J Urol 1994;1:99-113.
2. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
3. Brawer MK. Prostate specific antigen. A review. Acta Oncol 1991;30:161-8.
4. Oesterling JE, Jacobson SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men; establishment of age-specific reference ranges. J Am Med Assoc 1993;270:860-4.
5. Carter HB, Pearson JD, Metter EJ, Braut LJ, Cahn DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J Am Med Assoc 1992;267:2215-20.
6. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Ritenhouse HG, Ratliff TL, et al. Evaluation of free serum prostate-specific antigen to improve specificity of prostate cancer screening. J Am Med Assoc 1995;274:1214-20.
7. Egawa S, Soh S, Ohori M, Uchida T, Gohji K, Fujii A, et al. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan. Cancer 1997;79:90-8.
8. Kuriyama M, Kawada Y, Arai Y, Maeda H, Egawa S, Koshiba K, et al. Significance of free to total PSA ratio in men slightly elevated serum PSA levels: a cooperative study. Jpn J Clin Oncol 1998;28:661-5.
9. Imai K, Yamanaka H, Kubota Y, Miki M, Ito T, Akaza H, et al. Clinical utility of the free prostate specific antigen (PSA), antichymotrypsin-complexed PSA and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay 'E-plate EIKEN PSA'. Hinyokika Kiyo 1998;44:755-63 (in Japanese).
10. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. A prospective multicenter clinical trial. J Am Med Assoc 1998;279:1542-7.
11. Carlson GD, Calvanese CB, Partin AW. An algorithm combining age, total prostate-specific antigen (PSA) and percent free PSA to predict prostate cancer: results on 4298 cases. Urology 1998;52:455-61.
12. Abrahamsson PA, Kuriyama M. Molecular forms of serum prostate-specific antigen: The clinical usefulness of percent free PSA to discriminate prostate cancer from BPH. Hinyokika Kiyo 1998;11:925-30 (in Japanese).
13. Benson MC, Whang IS, Pantuck AP, Ring K, Kaplam SA, Olsson CA, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:817-21.
14. Uno H. Clinical significance of PSA-density in differential diagnosis between BPH and early stages prostate cancer. Nippon Hinyokika Gakkai Zasshi 1995;86:1776-83 (in Japanese).
15. Kuriyama M. The evaluation of PSA molecular forms, molecular ratio and PSAD in cases showing slightly elevated serum PSA values for screening prostate cancer. Hinyoki-Geka 1998;11:925-30 (in Japanese).
16. Akimoto S, Ichikawa S, Ito H. Relationship of prostate-specific antigen levels to prostate volume and age in mass screening subjects. Urol Int 1998;60:216-9.
17. Kuriyama M, Akimoto S, Akaza H, Arai Y, Usami M, Imai K, et al. Comparison of various assay system for prostate-specific antigen standardization. Jpn J Clin Oncol 1992;22:393-9.
18. Kuriyama M, Uno H, Ueno K, Hamamoto Y, Vihn PQ, Ban Y. Comparative study of the assays for prostate-specific antigen molecular forms. Jpn J Clin Oncol 1999;29:303-7.
19. Japanese Urological Association and Japanese Pathological Society. General Rules for Clinical and Pathological Studies on Prostate Cancer, 2nd ed. Tokyo: Kanahara 1992.
20. SPSS. Advanced Statistics 7.5J. Chicago: SPSS 1998.
21. Ban Y, Wang MC, Watt KW, Loor R, Chu TM. Proteolytic activity of human prostate-specific antigen. Biochem Biophys Res Commun 1984;123:482-8.
22. Brawer MK, Meyer GE, Letran JL, Bankson DD, Morris DL, Yeung KK, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998:52;372-8.
23. Imai K, Yamanaka H. Screening examination for prostate cancer. Early detection and mass screening. Nippon Hinyokika Gakkai Zasshi 1993;84:1175-87 (in Japanese).